Scientific publications

The association of -308G>A polymorphism of TNF gene with the development of non-alcoholic steatohepatitis (NASH) in the Russian population has been demonstrated for the first time. Carriers of the A allele for the TNF gene marker -308G>A have significantly increased risk of NASH development, OR = 1.69 (1.05; 2.71). Carriage of A allele for this marker is predictive for increasing basal levels of HDL and lowering LDL and IL-10 in the blood of healthy people. In patients with NASH, depending on the genotype for the marker -308G>A of TNF gene, are observed differences in the change in levels of the indicators of hepatocellular damage (ALT, AST), activity of hepatocyte apoptosis (TPS) and activation of specific humoral immunity (gamma-globulin) during therapy with UDCA in a dose of 10-15 mg/kg for 4-6 weeks. The carriers of A allele for the TNF gene polymorphic marker -308G>A are more sensitive to UDCA therapy compared with genotype GG carriers.